Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.32 |
| ▸ | CFD | P00746 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12752017 | 0.84 | KMT2A (0.41) | NPC1RAB9A | |
| SCHEMBL10182417 | 0.84 | KMT2A (0.41) | NPC1RAB9A | |
| SCHEMBL15586735 | 0.84 | KMT2A (0.41) | NPC1RAB9A | |
| SCHEMBL15773712 | 0.84 | KMT2A (0.41) | NPC1RAB9A | |
| SCHEMBL18901586 | 0.84 | USP30 (0.50) | USP30NPC1RAB9ACASP3SENP8 | |
| SCHEMBL12686982 | 0.84 | USP30 (0.50) | USP30NPC1RAB9ACASP3SENP8 | |
| SCHEMBL1294187 | 0.83 | ALDH1A1 (0.34) | USP30NPC1RAB9A | |
| SCHEMBL1294189 | 0.83 | ALDH1A1 (0.34) | USP30NPC1RAB9A | |
| SCHEMBL1293617 | 0.83 | L3MBTL1 (0.41) | USP30NPC1 | |
| SCHEMBL1293616 | 0.83 | L3MBTL1 (0.41) | USP30NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2012018325-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| WO-2009102633-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885NPC1 65/4885RAB9A 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.